Thursday’s trading has closed, but MDGL is being traded in the after-hours session. After-Hours quote »
As of 4:00pm ET
| -0.30 / -1.88%|
Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. The company offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal Pharmaceuticals was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
|Paul A. Friedman||Chairman, President & Chief Executive Officer|
|Marc R. Schneebaum||Chief Financial Officer & Senior Vice President|
|Rebecca A. Taub||Director & Chief Medical Officer|